Meniere Disease Clinical Trial
Official title:
A Randomized, Prospective, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Effectiveness of a Combination of Lamotrigine and Bupropion to Treat Meniere's Disease
This is a double-blind, placebo-controlled clinical trial to assess whether treatment with lamotrigine and bupropion is more effective than placebo to reduce definitive Meniere's vertigo attacks (DMVA) and dizziness in patients with Meniere's disease. Thirty four participants will be randomized to treatment or placebo groups. Each participant will take part in the trial for 34 weeks, or approximately 9 months.
Status | Recruiting |
Enrollment | 34 |
Est. completion date | December 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult participants, male and female aged 18 years or older - Diagnosis of definitive unilateral Meniere's disease according to the AAO-HNS 1995 criteria, confirmed by an ENT or qualified medical professional - Be experiencing active vertigo - Be in good general health as evidenced by medical history or, otherwise, have all other co-existing medical or psychiatric conditions stable, and or no greater than moderate in severity, as determined by the PI - Females of childbearing potential must use at least two forms of acceptable contraception, or remain abstinent; male participants must be willing to use condoms or other methods to ensure effective contraception with a partner - Be willing to comply with all study procedures and availability for the duration of the study - Be able to provide informed written consent, including agreement to privacy language either within the informed consent or in ancillary documents compliant with Health Insurance Portability and Accountability Act (HIPAA) before the initiation of any study-related procedures Exclusion Criteria: - A diagnosis of bilateral Meniere's disease according to the AAO-HNS 1995 criteria, confirmed by an ENT or qualified medical professional - Be pregnant or lactating - Have active migraine-associated vertigo - Not be able to accurately identify and report episodes of vertigo - Diagnosis of any other neuro-otologic disease or major vestibular abnormality found during screening that could confound the evaluation of Meniere's symptoms - Have a history of intolerance or sensitivity to lamotrigine - Previously failed the study drug - Received an intratympanic gentamicin injection(s) or endolymphatic sac surgery within in the last year - Have a family history of unexplained deafness - Have any current diseases or conditions that may be associated with an altered perception of processing stimuli - Have a history of substance abuse within the preceding 6 months prior to screening - Have non-vertiginous dizziness (orthostatic or panic disorder) unless it could be clearly differentiated from Meniere's attacks by the participant |
Country | Name | City | State |
---|---|---|---|
United States | Dent Neurologic Institute | Amherst | New York |
Lead Sponsor | Collaborator |
---|---|
Dent Neuroscience Research Center | Cures Within Reach, Dent Family Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in patients' tinnitus from baseline to the end of treatment. | Between groups comparisons of Tinnitus Handicap Index (THI) at Week 27 compared to the baseline visit at the end of the lead-in phase. THI at baseline compared to evaluation at end of treatment.
Score range from 0-100 with higher numbers representing a more severe tinnitus handicap. |
Baseline (Week 1) and Visit 8 (Week 27) | |
Other | Change in patients' hearing loss from baseline to the end of treatment. | Between groups comparisons of hearing loss at Week 24 compared to the baseline visit at the end of the lead-in phase. Hearing loss measured based off the pure-tone average at 500 Hz, 1000 Hz, 2000 Hz, and 3000 Hz measured in dB from audiometric report taken at Visit 1 and Visit 8. | Baseline (Week 1) and Visit 8 (Week 27) | |
Primary | Change in Ménière's vertigo attack frequency between groups | Number of Definitive Ménière's Vertigo attacks (DMVA), Number of Dizziness Days and overall dizziness severity during each 4-week of titration, and treatment compared to the 4-week lead-in phase. Vertigo ratings will be collected on a daily symptom diary throughout the study. DMVA is defined as vertigo for more than 20 minutes and corresponds to a vertigo rating of 3 or 4 on the daily symptom diary. A Dizziness Day is defined as vertigo rating of 1, 2, 3 or 4 on the daily symptom diary. Dizziness severity is the sum of all ratings (0-4) during each 4-week period. | Duration of lead-in to completion at week 30 | |
Primary | Change in Ménière's vertigo attack frequency lamotrigine alone compared to lamotrigine and bupropion | Number of Definitive Ménière's Vertigo attacks (DMVA), Number of Dizziness Days and overall dizziness severity during each 4-week of treatment of lamotrigine alone and treatment of bupropion and lamotrigine.Vertigo ratings will be collected on a daily symptom diary throughout the study. DMVA is defined as vertigo for more than 20 minutes and corresponds to a vertigo rating of 3 or 4 on the daily symptom diary. A Dizziness Day is defined as vertigo rating of 1, 2, 3 or 4 on the daily symptom diary. Dizziness severity is the sum of all ratings (0-4) during each 4-week period. | Week 1 to Week 27 | |
Secondary | Changes in patients' self-assessment of dizziness | Between groups comparisons of Dizziness Handicap Inventory (DHI) at Week 27 compared to the baseline visit at the end of the lead-in phase. DHI at baseline compared to evaluation at end of treatment.
Scores range from 0-100 with higher scores meaning more severe dizziness handicap |
Baseline (Week 1) and Visit 8 (Week 27) | |
Secondary | Changes in patients' self-assessment of overall affect of symptoms | Between groups comparisons of Ménière's Disease Patient-Oriented Symptom-Severity Index (MDPOSI) at Week 27 compared to the baseline visit at the end of the lead-in phase. MDPOSI at baseline compared to evaluation at end of treatment.
Scores range from 0-80 with higher numbers indicating more frequent and severe symptoms. |
Baseline (Week 1) and Visit 8 (Week 27) | |
Secondary | Changes in patients' self-assessment of symptom impact on daily life function | Between groups comparisons of Ménière's Disease Self-Assessment (MDSA) at Week 27 compared to the baseline visit at the end of the lead-in phase. MDSA at baseline compared to evaluation at end of treatment.
Scores range from 1-6 with higher numbers representing Ménière's Disease symptoms having a greater affect on the patient's ability to function in daily life. |
Baseline (Week 1) and Visit 8 (Week 27) | |
Secondary | Changes in patients' self-assessment of depression | Between groups comparisons of Patient Health Questionnaire-9 (PHQ-9) at Week 27 compared to the baseline visit at the end of the lead-in phase. PHQ-9 at baseline compared to evaluation at end of treatment.
Scores range from 0-27 with higher numbers meaning more severe depression. |
Baseline (Week 1) and Visit 8 (Week 27) | |
Secondary | Changes in patients' self-assessment of anxiety | Between groups comparisons of General Anxiety Disorder-7 (GAD-7) at Week 27 compared to the baseline visit at the end of the lead-in phase. GAD-7 at baseline compared to evaluation at end of treatment.
Scores range from 0-21 with higher numbers meaning more severe anxiety. |
Baseline (Week 1) and Visit 8 (Week 27) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04835688 -
Ventilation Tube Insertion for Unilateral Menière's Disease
|
N/A | |
Recruiting |
NCT05851508 -
The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease
|
Phase 3 | |
Not yet recruiting |
NCT05322538 -
Menier's Disease - Bone Density Study
|
N/A | |
Completed |
NCT05328895 -
Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
|
N/A | |
Completed |
NCT04569175 -
Non Enhanced Labyrinth Imaging for the Detection of Endolymphatic Hydrops in Meniere's Disease "NELI Study"
|
N/A | |
Not yet recruiting |
NCT05582148 -
Meniere Disease and Hearing Aids
|
N/A | |
Completed |
NCT05844657 -
Comprehensive Evaluation in Patients With Meniere's Disease
|
||
Completed |
NCT04902963 -
What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube?
|
N/A | |
Completed |
NCT04686695 -
Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Meniere Disease
|
N/A | |
Recruiting |
NCT04815187 -
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
|
Phase 4 | |
Recruiting |
NCT06278129 -
Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière's Disease
|
||
Recruiting |
NCT04766853 -
Verification of the Efficacy/Safety of the Intratympanic Drug Delivery for Hearing Loss
|
Phase 1/Phase 2 | |
Recruiting |
NCT04370366 -
Imaging of Endolymphatic Hydrops at 7T MRI
|
||
Enrolling by invitation |
NCT03520322 -
A Study of a Mastoid Device in Subjects With Ménière's Disease
|
N/A | |
Not yet recruiting |
NCT05424302 -
Effect of Peripheral Vestibular Disease Location on Outcomes Following Home-based Virtual Reality Vestibular Therapy
|
N/A | |
Withdrawn |
NCT04674735 -
Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease
|
Phase 1 | |
Recruiting |
NCT03795675 -
CI Following VS Removal or Labyrinthectomy
|
N/A | |
Completed |
NCT04218123 -
Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02371798 -
Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?
|
N/A | |
Completed |
NCT05960786 -
Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand
|
N/A |